• Novo Nordisk accuses Eli Lilly of using misleading advertising practices.
• The lawsuit focuses on comparative claims between weight-loss drugs Zepbound and Wegovy.
• Novo seeks corrective advertising and an injunction against Eli Lilly's current ads.
• The global obesity drug market is projected to reach $120 billion by 2030.
• Eli Lilly defends its advertising strategy, citing legitimate clinical evidence.

Novo Nordisk has initiated legal proceedings against Eli Lilly, alleging "false and materially misleading" advertising claims regarding their weight-loss and diabetes treatments. The lawsuit, filed in U.S. District Court in New Jersey, accuses Eli Lilly of relying on outdated clinical data to promote its products Zepbound and Mounjaro as superior to Novo's Wegovy and Ozempic. Novo contends that Lilly's advertisements compare the highest doses of its drugs with lower doses of Novo's medicines, thereby omitting important information on higher doses available after new FDA approvals, according to Reuters and BBC.

In its complaint, Novo asserts that it has "multiple violations" of false advertising and unfair competition laws by Eli Lilly, which has employed misleading ad campaigns that misrepresent the efficacy of their drugs. Novo general counsel John Kuckelman emphasized that "healthcare companies have a responsibility to keep their public claims accurate and current," criticizing disclaimed information as insufficient to mitigate consumer confusion caused by Eli Lilly's ads, as reported by Los Angeles Times and CBS News.

As the two pharmaceutical companies vie for dominance in the lucrative obesity drug market—estimated to exceed $120 billion by 2030—Novo is pursuing court orders to halt Eli Lilly's advertisements and institute corrective advertising that reflects accurate claims based on the latest scientific evidence. Novo argues that Eli Lilly's comparisons are outdated and misleading, specifically regarding clinical trials that do not utilize the most recent dosing information. This lawsuit follows a cease-and-desist letter sent to Eli Lilly back in April, which went unanswered, according to Channel News Asia and Los Angeles Times.

Eli Lilly, on the other hand, has defended its advertisements, claiming they are grounded in the most direct scientific evidence available from clinical trials like Surmount-5, which reportedly provide straightforward comparisons between the products. The contention from Eli Lilly suggests that instead of competing on the merits of their products, Novo is attempting to restrict the dissemination of legitimate trial results, as noted in both Reuters and CBS News.